Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Venture Fund Selects Neurostim Device Maker SetPoint Medical As First Investment

Executive Summary

A $50 million venture fund set up by pharmaceutical giant GlaxoSmithKline has chosen vagus nerve stimulation device start-up SetPoint Medical, a company currently focused on treatments for autoimmune diseases, as its first investment. The move highlights the growing importance of device-mediated therapies for a wide range of common, chronic conditions.


Related Content

VC Deals Analysis: Liquid Biopsy Summons Yet Another Top A-Lister
Electroceuticals: Drug-Like Effects, Without The Drugs
The Year In Review: Device Trends To Watch In 2014
Medtech 2013: Device Companies Go Where The Growth Is
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
VC Funding In 2013: Some Impressive Device Rounds, But Momentum Shifts To Biotech
ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache
Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market
Neuromodulation Market: Innovation Brings High-Growth Rewards


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts